QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord1 Biogen’s second rare disease therapy… Read More
Partnership marks AbbVie’s entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global infrastructure for developing and… Read More
If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time… Read More
A new study led by UBC faculty of medicine researchers is shedding light on how the brain begins to heal itself after a stroke, identifying the specific brain cells that… Read More
Getinge is introducing its new DPTE®-FLEX, a manual, externally openable port. This new port enhances safety, efficiency, and compliance in pharmaceutical manufacturing by allowing secure, gloveless transfers, which reduces human… Read More
